Cleerly’s AI-Driven Cardiac Imaging gets a US$106M boost

USA—Cleerly, a leader in advanced cardiovascular imaging, has successfully raised $106 million in its Series C extension funding round.

This significant investment was led by Insight Partners, a global software investor, and supported by Battery Ventures, with participation from Cleerly’s existing investors.

The new funds will help Cleerly scale its commercial growth and expand its clinical research, supporting healthcare professionals in improving patient outcomes across the coronary care pathway.

Cleerly’s mission is to establish a new standard of care for heart disease through the use of FDA-cleared solutions powered by artificial intelligence (AI).

The company’s advanced non-invasive imaging technology, which uses computed tomography (CT), allows for a thorough analysis of coronary artery disease.

The technology is grounded in scientific research and millions of medical images, providing more accurate assessments of the disease.

James K. Min, MD, Founder and CEO of Cleerly, expressed his enthusiasm about the funding, calling it a major milestone for the company.

He emphasized that this investment would enable Cleerly to expand its commercial reach, especially after recent achievements like securing Medicare coverage and obtaining a CPT Category I code for advanced plaque analysis.

Dr. Min also spoke passionately about Cleerly’s mission to make advanced cardiac care accessible to more patients and finally eliminate heart attacks.

Scott Barclay, Managing Director at Insight Partners, also shared his excitement about supporting Cleerly’s groundbreaking work.

He praised Cleerly’s AI-driven approach to advanced cardiovascular imaging, noting that it is setting a new standard in diagnostic tools for coronary artery disease.

 Barclay highlighted that with this investment, Insight Partners looks forward to helping Cleerly expand its impact and make this life-saving technology accessible to more patients and healthcare systems across the country.

He pointed out that the recent Medicare and CPT I code approvals demonstrate the value and readiness of Cleerly’s technology in the fight against heart disease.

Barclay also discussed the broader significance of cardiovascular disease, which remains the leading cause of death globally and costs the U.S. economy $422 billion annually.

 He noted that before Cleerly, healthcare providers lacked a reliable, non-invasive method to assess plaque burden in patients fully.

Cleerly’s software, which analyzes non-invasive images, offers a breakthrough in identifying heart disease early, similar to how mammograms and colonoscopies have revolutionized early breast and colon cancer detection.

While Cleerly faces competition from companies like HeartFlow and Elucid, the growing need for heart disease screening for aging populations suggests there is room for multiple players to succeed in this critical market. 

Sign up HERE to receive our email newsletters with the latest news and insights from Africa and around the world, and follow us on our WhatsApp channel for updates.